|Bid||15.72 x 800|
|Ask||15.80 x 1400|
|Day's Range||15.48 - 15.80|
|52 Week Range||13.85 - 26.31|
|Beta (5Y Monthly)||2.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2021 - Nov 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||54.57|
Subscribe to Yahoo Finance Plus to view Fair Value for MIRMLearn more
Mirum Pharmaceuticals Inc said on Wednesday its drug became the first U.S. approved therapy for treating itching in patients with a rare liver disorder called Alagille syndrome (ALGS). Mirum priced the drug, to be made available for distribution immediately under brand name Livmarli, at $1,550 per unit.
FOSTER CITY, Calif., September 29, 2021--FDA Approves LIVMARLI as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with ALGS
Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.